Bevacizumab for ophthalmic diseases

Expert Review of Ophthalmology

Volumn 2, Issue 3, 2007, Pages 369-378

  Michels, Stephan ^a   Prager, Franz ^a   Bakri, Sophie J ^b   Wachtlin, Joachim ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Department of Ophthalmology ^*  (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AMD; angiogenesis; anti VEGF; Avastin ; bevacizumab; choroidal neovascularization; eye; macular degeneration; neovascularization; ocular; vascular endothelial growth factor

Indexed keywords

EID: 63149123795     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.3.369     Document Type: Article

References (95)

1. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol. Scand. 84, 282–288 (2006).
2. Wang F, Rendahl KG, Manning WC et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest. Ophthalmol. Vis. Sci. 44, 781–790 (2003).
3. Apte RS, Barreiro RA, Duh E et al. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest. Ophthalmol. Vis. Sci. 45, 4491–4497 (2004).
4. Kwak N, Okamoto N, Wood JM et al. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41, 3158–3164 (2000).
5. Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338–346 (2002).
6. Saishin Y, Saishin Y, Takahashi K et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195, 241–248 (2003).
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
9. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004).
10. Rosenfeld PJ, Heier JS, Hantsbarger G et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113, 632 (2006).
11. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112, 1048–1053 (2005).
12. Nguyen QD, Shah SM, Hafiz G et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113, e1 –e14 (2006).
13. Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112, 1035–1047 (2005).
14. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113, e1 –e12 (2006).
15. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic. Surg. Lasers Imaging 36, 336–339 (2005).
16. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging 36, 331–335 (2005).
17. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am. J. Health Syst. Pharm. 61, S21 –S26 (2004).
18. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288, 371–378 (1999).
19. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).
20. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993).
21. Brasch R, Pham C, Shames D et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J. Magn. Reson. Imaging 7, 68–74 (1997).
22. Ryan AM, Eppler DB, Hagler KE et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27, 78–86 (1999).
23. Tolentino MJ, Husain D, Theodosiadis P et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch. Ophthalmol. 118, 78–84 (2000).
24. Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26, 262–269 (2006).
25. Schraermeyer UA, Henke-Fahle S, Grisanti S et al. Evidence for transport of bevacizumab through the retina by muller cells in rabbits. ARVO 2006. Abstract 4169 (2006).
26. Feiner L, Barr EE, Shui YB et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26, 882–888 (2006).
27. Bakri SJ, Cameron JD, McCannel CA et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am. J. Ophthalmol. 142, 162–164 (2006).
28. Manzano RP, Peyman GA, Khan P et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26, 257–261 (2006).
29. Kiss C, Michels S, Prager F et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26, 877–881 (2006).
30. Ziemssen F, Warga M, Neuhann IM et al. Does intravitreal injection of bevacizumab have an effect on the blood–aqueus barrier function? Br. J. Ophthalmol. 90, 922 (2006).
31. Luke M, Warga M, Ziemssen F et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br. J. Ophthalmol. 90, 1178–1182 (2006).
32. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26, 270–274 (2006).
33. Luthra S, Narayanan R, Marques LE et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26, 512–518 (2006).
34. Spitzer MS, Wallenfels-Thilo B, Sierra A et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br. J. Ophthalmol. 90, 1316–1321 (2006).
35. Bakri SJ, Snyder M, Reid J et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (5), 855–859 (2007).
36. Gaudreault J, Fei D, Rusit J et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726–733 (2005).
37. Beer PM, Wong SJ, Hammad AM et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26, 871–876 (2006).
38. Peters S, Julien S, Heiduschka P et al. Anti-permeability and anti-proliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br. J. Ophthalmol. DOI: 109702v1 (2006) (Epub ahead of print).
39. Bakri SJ, Snyder MR, Pulido JS et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26, 519–522 (2006).
40. ®) for the treatment of neovascular age-related macular degeneration. ARVO 2006. Abstract 5231 (2006).
41. Geitzenauer W, Michels S, Prager F et al. [Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration]. Klin. Monatsbl. Augenheilkd. 223, 822–827 (2006).
42. Nguyen QD, Shah S, Tatlipinar S et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br. J. Ophthalmol. 89, 1368–1370 (2005).
43. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980–982 (2006).
44. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113, 363–372 (2006).
45. Rich RM, Rosenfeld PJ, Puliafito CA et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26, 495–511 (2006).
46. Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26, 383–390 (2006).
47. Aisenbrey S, Ziemssen F, Volker M et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0471-7 (2006) (Epub ahead of print).
48. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 245, 68–73 (2007).
49. Yoganathan P, Deramo VA, Lai JC et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26, 994–998 (2006).
50. Aggio FB, Farah ME, Silva WC et al. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0412-5 (2006) (Epub ahead of print).
51. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch. Clin. Exp. Ophthalmol. 245 (5), 651–655 (2007).
52. Bashshur ZF, Bazarbachi A, Schakal A et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol. 142, 1–9 (2006).
53. Costa RA, Jorge R, Calucci D et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest. Ophthalmol. Vis. Sci. 47, 4569–4578 (2006).
54. Dhalla MS, Shah GK, Blinder KJ et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26, 988–993 (2006).
55. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging 37, 446–454 (2006).
56. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am. J. Ophthalmol. 98, 271–282 (1984).
57. Noma H, Minamoto A, Funatsu H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 244, 309–315 (2006).
58. Iturralde D, Spaide RF, Meyerle CB et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26, 279–284 (2006).
59. Jaissle GB, Ziemssen F, Petermeier K et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. Ophthalmologe 103 (6), 471–475 (2006).
60. Grisanti S, Biester S, Peters S et al. Intracameral bevacizumab for iris rubeosis. Am. J. Ophthalmol. 142, 158–160 (2006).
61. Iliev ME, Domig D, Wolf-Schnurrbursch U et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am. J. Ophthalmol. 142, 1054–1056 (2006).
62. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic. Surg. Lasers Imaging 37, 144–146 (2006).
63. Funatsu H, Yamashita H, Nakamura S et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113, 294–301 (2006).
64. Ogata N, Nishikawa M, Nishimura T et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am. J. Ophthalmol. 134, 348–353 (2002).
65. Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 20, 1474–1475 (2006).
66. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26, 275–278 (2006).
67. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26, 699–700 (2006).
68. Oshima Y, Sakaguchi H, Gomi F et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 142, 155–158 (2006).
69. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113, e1 –e15 (2006).
70. Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26, 1006–1013 (2006).
71. Haritoglou C, Kook D, Neubauer A et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26, 999–1005 (2006).
72. Laud K, Spaide RF, Freund KB et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26, 960–963 (2006).
73. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26, 1093–1094 (2006).
74. Sakaguchi H, Ikuno Y, Gomi F et al. Intravitreal injection of bevacizumab for choroidal neovascularization caused by pathological myopia. Br. J. Ophthalmol. 91 (2), 161–165 (2007).
75. Yamamoto I, Rogers AH, Reichel E et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br. J. Ophthalmol. 91 (2), 157–160 (2007).
76. Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0468-2 (2006) (Epub ahead of print).
77. Teixeira A, Moraes N, Farah ME et al. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol. Scand. 84, 835–836 (2006).
78. Siqueira RC, Costa RA, Scott IU et al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol. Scand. 84, 834–835 (2006).
79. Shah PK, Narendran V, Tawansy KA et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J. Ophthalmol. 55, 75–76 (2007).
80. Manzano R, Peyman G, Khan P et al. Inhibition of experimental corneal neovascularization by bevacizumab (AVASTIN). Br. J. Ophthalmol. DOI: 107912v1 (2006) (Epub ahead of print).
81. Amselem L, Cervera E, Diaz-Llopis M et al. Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye 21 (4), 566–567 (2007).
82. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26, 356–357 (2006).
83. Ziemssen F, Deuter CM, Stuebiger N et al. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0512-2 (2007) (Epub ahead of print).
84. Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin. Drug Saf. 5, 289–301 (2006).
85. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419–1431 (2006).
86. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432–1444 (2006).
87. D’Amico DJ, Masonson HN, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113, 992–1001 (2006).
88. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90, 1344–1349 (2006).
89. Pieramici DJ, Avery RL, Castellarin AA et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 26, 841–842 (2006).
90. Bakri SJ, Patel SP. Retinal pigment epithelial tear following intravitreal bevacizumab. Eye 21 (3), 424–425 (2007).
91. Gelisken F, Ziemssen F, Voelker M et al. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol. Scand. 84, 833–834 (2006).
92. Meyer CH, Mennel S, Schmidt JC et al. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br. J. Ophthalmol. 90, 1207–1208 (2006).
93. Nicolo M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur. J. Ophthalmol. 16, 770–773 (2006).
94. Shah CP, Hsu J, Garg SJ et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am. J. Ophthalmol. 142, 1070–1072 (2006).
95. US FDA Medwatch www.fda.gov/medwatch